• SUGCT Inhibition: What the Evidence Shows

  2026-10-23

  Wu et al. positioned succinylCoA:glutarate-CoA transferase (SUGCT) as a potentially actionable metabolic modifier in glutaric aciduria type 1 (GA1). Their evidence combined genetic cell models, a coupled enzyme assay, screening of an FDA-approved bioactive compound library, and crystallography. The results support biochemical inhibition by valsartan and losartan carboxylic acid, but they do not yet establish cellular efficacy, disease modification, or clinical repurposing.

• How PAI-1 Inhibition Changes Fibrinolysis Readouts

  2026-10-21

  Tiplaxtinin (PAI-039) is identified with inhibition of plasminogen activator inhibitor-1, a regulatory protein that restrains fibrinolysis. The most useful interpretation is to separate direct effects on PAI-1 activity from downstream changes in plasmin generation, fibrin degradation, or cellular behavior.

• NHE1 as a Mediator of Octanal-Driven Atherosclerosis

  2026-10-21

  A 2025 Scientific Reports study used mouse and macrophage models to place NHE1 downstream of octanal–Olfr2 signaling in atherosclerosis. Its results connect NHE1 activity with calcium elevation, reactive oxygen species, NLRP3-associated inflammation, foam-cell formation and plaque burden, while leaving important questions about human relevance and pathway specificity.

• NF 449: What the Evidence Actually Supports

  2026-10-20

  NF 449 has been described both as a potent antagonist of recombinant P2X1 channels and as a relatively selective inhibitor of Gsα-dependent signaling. These findings are scientifically relevant but arise from different assay systems, so they should not be treated as interchangeable evidence for platelet specificity, antithrombotic activity, or clinical utility.

• What an SREBP Drug Screen Really Established

  2026-10-19

  Ishida and colleagues developed a lipid-dependence-based screen for FDA-approved compounds and identified 13 drugs that suppressed SREBP-associated responses in cancer-cell models. The study is important as a screening and target-hypothesis framework, but its results do not establish direct SREBP binding, clinical anticancer activity, or equivalence between the screened collection and the separately marketed DiscoveryProbe™ FDA-approved Drug Library.

• AM580: A Source-Bounded RARα Agonist Overview

  2026-10-19

  AM580 is described by APExBIO as a selective RARα agonist associated with retinoid-responsive transcription, cellular growth suppression, apoptosis-related readouts, and reduced tumor growth in a named mouse model. Because the available evidence is supplier documentation rather than an identity-matched publication, the potency values, causal mechanism, combination effects, and translational relevance remain bounded by missing assay details, comparators, sample sizes, and uncertainty estimates.

• Visomitin (SKQ1): Evidence and Scope

  2026-10-18

  The APExBIO product description identifies Visomitin, also called SKQ1, as a mitochondria-targeted antioxidant associated with mitochondrial ROS and oxidative-stress research. That description supports a documented identity and proposed mechanism, but it does not provide matched experimental evidence, assay results, comparators, effect sizes, or clinical validation.

• Mouse Lung Organoid Kit: Evidence and Scope

  2026-10-17

  The APExBIO Mouse Lung Organoid Kit (SKU K2940) is identifiable as a product intended for a mouse lung organoid research context, but the available product information does not document its composition, molecular mechanism, readouts, validation data, or study-specific performance. No identity-matched research paper is available, so interpretation must remain limited to product identity and the general conceptual role implied by the name.

• ICI 118,551 Hydrochloride: Evidence Scope

  2026-10-16

  The APExBIO listing identifies ICI 118,551 hydrochloride as catalog item B1004, but the available product information contains no description, structural confirmation, mechanism statement, assay context, or identity-matched research evidence. This article therefore separates catalog identity from pharmacological claims and defines what cannot be concluded from the available record.

• How ATRA Reverses Cisplatin-Linked PARP Resistance

  2026-10-16

  Mei and colleagues reported that all-trans retinoic acid reduced molecular features associated with cisplatin-linked niraparib resistance in epithelial ovarian cancer models. The study supports a mechanistic hypothesis involving ALDH1A1, NAMPT, PARP1, checkpoint kinase 1, and NAD+ metabolism, but its preclinical design does not establish clinical efficacy, formal drug synergy, or applicability across defined BRCA or homologous-recombination subgroups.

• DiscoveryProbe Library: What the Evidence Supports

  2026-10-15

  The APExBIO DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is described as a 2,320-compound collection of clinically approved or pharmacopeia-listed bioactive molecules spanning multiple pharmacological classes. Its documented value is as a broad perturbation resource for conceptual drug repositioning screening and target-hypothesis generation; no identity-matched study, product-specific outcome, or comparative performance evidence is available here.

• CA-074: Mechanism, Product Identity, and Evidence

  2026-10-15

  CA-074 is described by APExBIO as a selective cathepsin B inhibitor whose reported biochemical potency and downstream effects span neurotoxicity, immune response modulation, and cancer metastasis models. Because no identity-matched research paper is available here, these claims should be interpreted as supplier-reported evidence rather than an independently verified literature record. The product description supports a mechanistic hypothesis, but it does not establish universal selectivity, clinical benefit, or causal attribution of every model-level outcome to cathepsin B.

• DiscoveryProbe™ FDA-Approved Library: Scope and Evidence

  2026-10-14

  APExBIO describes the DiscoveryProbe™ FDA-approved Drug Library (SKU L1021) as a 2,320-compound FDA-approved bioactive compound library spanning multiple pharmacological classes. The documentation supports a product-identity and scope overview, but not claims of screening performance, target discovery, or therapeutic efficacy: no identity-matched study, readout, comparator, sample size, or outcome statistics are provided.

• Angiopoietin–PEDF Signaling in Retinal Survival

  2026-10-14

  Younis and colleagues report an in vitro pathway in which Müller-cell angiopoietin signaling influences PEDF production and retinal neuronal survival. The findings support a glia-mediated mechanism, but they do not establish clinical neuroprotection or show that BAY-826 was used in the study. Supplier-reported potency for BAY-826 therefore should not be treated as evidence of activity, selectivity, or therapeutic relevance in these retinal models.

• What SLEV Helicase Structures Actually Show

  2026-10-13

  The reported SLEV helicase structure provides a mechanistic framework for target identification, but its docked compounds remain computational leads rather than validated antivirals. The study’s main limitations include modeled rather than experimentally resolved RNA binding, isolated-enzyme evidence, and no demonstrated cellular, animal, or clinical efficacy.

8078 records 1/539 page Next 12345 下5页 Last page